Stem cell firm Regeneus raising targets $10m
BY:TIM BOREHAM From:The Australian August 19, 2013 12:00AMIncrease Text SizeDecrease Text SizePrintREGENEUS executive chairman John Martin blanches at suggestions the regenerative medicine minnow is a poor man's alternative to stem-cell play Mesoblast, which commands a $1.9 billion market valuation."We are not a poor man's anyone -- we have our own story," Mr Martin said, adding "There's no doubt Mesoblast has done a good job priming the Australian market about stem-cell therapies."
LOGIN TO READ THE REST OF THIS ARTICLE
the australian
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |